The dose-related weight loss was also accompanied by improvements in cardiovascular disease risk factors….
Read More »Fetuin-A Levels Linked to Cardiovascular Disease Risk
Link between high fetuin-A and lower cardio risk modified by T2DM, obesity, insulin resistance….
Read More »Metformin or Glipizide to Prevent Cardiovascular Events?
Compared with glipizide, long-term therapy with metformin leads to a reduction in major cardiovascular events in patients with type 2 diabetes….
Read More »Multivitamins Do Not Reduce Cardiovascular Events
A study with 15,000 middle-aged male physicians using multivitamins for more than 10 years showed no benefit in reducing cardiovascular events….
Read More »Lifetime Risk of Developing Cardiovascular Disease Substantial
Even in men and women with an optimal cardiovascular disease (CVD) risk factor profile, the lifetime risk estimate for CVD is greater than 30%, and is more than 50% for men and women overall….
Read More »Sulfonylurea’s Cardiotoxicity Probed
The risk of ischemic events may be higher with a specific subclass of sulfonylureas….
Read More »Diabetes Increases Risk of Cardiovasular Events by 30%
Diabetes was associated with a 30% increased risk of developing cardiovascular conditions, including heart disease and stroke….
Read More »GLP-1 Agonists and Cardiovascular Health, Part 2 of 2
In this week’s Homerun Slides, we have Part 2 of our special slide collection of GLP-1 Agonists and Cardiovascular Health. Topics covered include: Cardiac Actions of GLP-1, and Effects of GLP-1 Agonists on Inflammatory Markers…. Link to download (.ppt format): GLP-1 Agonists and Cardiovascular Health, Part 2 of 2 Other sets …
Read More »GLP-1 Agonists and Cardiovascular Health, Part 1 of 2
This set of Homerun Slides put together by Diabetes In Control staff is specifically geared towards the cardiovascular benefits of incretins. Link to download (.ppt format): GLP-1 Agonists and Cardiovascular Health, Part 1 of 2 Other sets in this series: GLP-1 Agonists and Cardiovascular Health, Part 2 of 2 See more GLP-1 Agonist …
Read More »The Effects of GLP-1 on Cardiovascular Health
Tina Burge, Doctor of Pharmacy Candidate, FAMU College of Pharmacy Reviewed by Dave Joffe, BSPharm, CDE It’s well-known that patients with diabetes have an increased risk of cardiovascular disease when compared to patients without diabetes. Diabetes type 2 has a high prevalence in the obese (BMI ³ 25kg/m2) and overweight …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.